Advertisement Argenta in drug discovery service pact with Janssen Pharma - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Argenta in drug discovery service pact with Janssen Pharma

Argenta Discovery 2009 Limited, an affiliate of Galapagos, has signed a drug discovery service agreement with Janssen Pharmaceutica, aimed at delivering novel cancer drug candidates.

The total contract value for Galapagos for the initial phase of the collaboration could exceed €33.5m over a 5 year period pending the achievement of certain milestones.

As per the agreement, Argenta is expected to provide medicinal chemistry and biology for a number of Janssen oncology targets.

Under the current agreement, Argenta is expected to perform hit-to-lead and lead optimisation for a number of Janssen oncology targets, and also activities up to pre-clinical candidate selection.

However, Janssen retains the option to extend the services beyond the initial set of targets, up to a total of 15 targets.

Galapagos CEO Onno van de Stolpe said that they are seeing an increased demand for longer term, integrated deals in their services business, which access a variety of their drug discovery capabilities and with Argenta’s track record of delivering on integrated drug discovery programs.